MABLINK
LIVE

Serial Number

79299550

Owner

MABLINK BIOSCIENCE

Attorney

John R. Rudolph

Filing Date

Jul 15, 2020

Add to watchlist:

No watchlists yet
View on USPTO

MABLINK Trademark

Serial Number: 79299550 • Registration: 6532856

MABLINK is a trademark filed by MABLINK BIOSCIENCE on July 15, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

MABLINK BIOSCIENCE (2 trademarks)

14 rue Waldeck-Rousseau

Entity Type: 34

Trademark Details

Filing Date

July 15, 2020

Registration Date

October 26, 2021

Published for Opposition

August 10, 2021

Goods & Services

Chemical, biochemical, biological and biotechnological preparations for use in industry and science ; chemical substances for the manufacture of pharmaceutical products for non-medical purposes, namely, for use in manufacturing of antibody conjugates ; chemical substances for tethering molecules, in particular chemical substances for tethering molecules for cancer therapy, for research in active substances and medicines other than for medical or veterinary purposes; chemical substances for the formation of antibody conjugates for use in laboratories, other than for medical or veterinary purposes ; chemical reagents for scientific purposes other than for medical or veterinary purposes; reagents for scientific or medical research; chemical, biochemical and biological reagents for scientific or medical research use; chemicals for bioconjugation, reversible cysteine protection, surface modification, and the production of prodrugs for use in laboratories, other than for medical or veterinary purposes; antibodies and antibody conjugates for scientific purposes, other than for medical or veterinary purposes; antibodies for scientific or medical research; molecules and biomolecules, namely, reagents, antibody fragments, antibodies, all intended for fundamental research and development, medical research and scientific diagnosis; Diagnostic products for scientific or research use related to conjugated antibodies, namely, diagnostic preparations for scientific use

Preparation, transformation, processing of biopharmaceutical materials, reagents, antibodies and conjugated antibodies, namely, biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process; processing and transformation of biopharmaceuticals on behalf of third parties; custom manufacturing of scientific, medical, chemical, biochemical and pharmaceutical products, namely, conjugated antibodies and drug conjugate by biopharmaceutical compounders

Pharmaceutical preparations for the treatment of cancer ; pharmaceutical products for the prevention or treatment of human diseases, namely, the treatment of cancer; chemical, biological and biochemical products for medical and pharmaceutical use, namely, antibody-drug conjugates and any protein combined with a drug, a polynucleotide, another protein, a chemical entity, or another functional entity, and used as medical binders or fillers; pharmaceutical preparations, namely bioconjugates, intended for the diagnosis and treatment of diseases, namely, cancer ; antibody products, namely, antibody or protein bioconjugates for the medical diagnosis and treatment of cancer, namely, antibody/protein drug conjugates, antibody/protein labeled conjugates and antibody/protein imaging agent conjugates; delivery devices for antibodies, namely, drugs delivery agent in the form of antibodies drug conjugates that facilitate the delivery and action of medical preparations ; molecules and biomolecules, namely, reagents, antibody fragments, antibodies, all intended for medical diagnosis and disease treatment; pharmaceutical products, preparations and medical articles, namely, antibodies, antibody conjugates and active principles and antibody conjugates for medical purposes; chemical reagents for medical use, namely, chemical reagents to bind molecules for medical use; chemical reagents for the functionalization of biomolecules for medical use

Medical services; medical services, namely, medical modification of antibodies; medical services in the field of personalized medicine; medical advice and information services in the field of biopharmaceutical products; pharmaceutical advice; consultancy services in the field of medicine

Scientific research; biological and chemical research; biochemical research and development; research and development in the pharmaceutical, biomedical and biotechnological fields, namely, research into antibodies, including conjugated antibodies; research and development in the fields of biological development and biomanufacturing; laboratory research, analysis, evaluation, development and clinical testing of therapeutic, preventive and diagnostic compositions and treatments; conducting scientific and medical research for third parties in the field of pharmaceuticals and cancer therapy ; consultancy in the field of pharmaceutical research, chemistry, biotechnology; Performance of chemical analyses, namely, custom synthesis of chemical substances; chemical and biological development services, namely custom design and development of chemical reagents and biochemical assays; services of a chemist and a biologist; scientific laboratory services namely chemical and biological laboratory services; scientific laboratory services, namely, laboratory services concerning the modification and production of reagents, antibodies and conjugated antibodies; scientific research and development services in the field of reagent development and production of antibodies and conjugated antibodies; conducting chemical and biological analyses; customized design and development of chemical reagents, antibodies and conjugated antibodies; development of chemical substances, namely, chemical substances to tether molecules and in particular technological platforms for the creation or improvement of antibody-drug conjugates or any protein combined with a drug, a polynucleotide, another protein, a chemical entity or another functional entity intended for industry and science

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Apr 28, 2024 NREP
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 14, 2024 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 14, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 14, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 14, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 14, 2024 COAR
FINAL DECISION TRANSACTION PROCESSED BY IB
May 9, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 18, 2022 FICS
FINAL DISPOSITION PROCESSED
Apr 18, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 26, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Oct 26, 2021 R.PR
NOTIFICATION PROCESSED BY IB
Aug 15, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 10, 2021 NPUB
PUBLISHED FOR OPPOSITION
Aug 10, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jul 28, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jul 28, 2021 OP2R
NEW REPRESENTATIVE AT IB RECEIVED
Jul 23, 2021 NREP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 21, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 5, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 24, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 24, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 24, 2021 TROA
REFUSAL PROCESSED BY IB
Jan 24, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 5, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jan 5, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 19, 2020 RFCR
NON-FINAL ACTION WRITTEN
Dec 18, 2020 CNRT
ASSIGNED TO EXAMINER
Dec 17, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 15, 2020 MAFR
ASSIGNED TO EXAMINER
Dec 11, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 11, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 10, 2020 REPR